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Protoporphyria (PP) is an inherited disorder of porphyrin metabolism in man in which there is excessive
accumulation and excretion of protoporphyrin. Recently, a similar disorder has been described in cattle. In
this report, the clinical, biochemical, and genetic features of bovine and human PP are compared.
Human and bovine PP are characterized by photosensitivity and elevation of erythrocyte and fecal
protoporphyrin levels. In both disorders, a deficiency of heme synthase activity is present in all tissues which
have been examined. The diseases differ clinically in that hepatobiliary disease has been found thus far only in
human PP. They also have different inheritance patterns. Human PP is an autosomal dominant disease, while
initial studies-strongly suggest that there is an autosomal recessive pattern of inheritance in bovine PP.
INTRODUCTION
The porphyrias are a group of inherited disorders in man in which there is
increased formation and excretion of porphyrins and/or porphyrin precursors [1,2].
These compounds are intermediates in the biosynthetic pathway for heme, the
prosthetic group for hemoproteins such as hemoglobin and the cytochromes.
The biochemical abnormalities characteristic of congenital erythropoietic por-
phyria have been found in animals, and the disease has previously been compared to
that in humans [3,4]. Recently, an inherited disorder in cattle has been described in
which the biochemical abnormalities are the same as in human protoporphyria (PP)
[5,6]. This is the first animal model of the human disease. In this review, PP in cattle
is compared to that in humans in order to identify both similarities and differences
between the diseases.
Biochemical and Enzymatic Abnormalities (Table 1)
The biochemical manifestations in each oftheinherited porphyrias in man reflect a
partial deficiency in the activity of a specific enzyme in the heme biosynthetic
pathway. An accumulation of porphyrins and/or porphyrin precursors occurs
because of the partial enzymatic defect.
The first reaction in the heme biosynthetic pathway, in which glycine condenses
with succinyl-CoA to form 8-aminolevulinic acid (ALA), is the rate-limiting step
[1,2]. The reaction is catalyzed in the mitochondria by ALA synthase. Hepatic
activity of ALA synthase may increase markedly during acute attacks of porphyria,
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TABLE I
Comparison of Human and Bovine Protoporphyria
Human Bovine
Clinical
Photosensitivity + +
Hepatobiliary disease Rare 0
Anemia 0 to mild 0
Biochemical
Erythrocyte t Protoporphyrin * Protoporphyrin
Plasma t Protoporphyrin Not determined
Feces t Protoporphyrin + Protoporphyrin
Enzvmatic
Heme synthase (Ferrochelatase) * In all tissues In all tissues
ALA synthase
(liver) Normal to *
(bone marrow) Normal to f Not determined
Genetic
Inheritance pattern Dominant Recessive (?)
presumably as a secondary phenomenon in order to maintain adequate formation of
heme [1,2].
Two molecules of ALA undergo dehydration condensation in the cytoplasm to
form porphobilinogen. The pathway's next steps involve porphyrinogens, which are
colorless, reduced compounds [1,2]. Uroporphyrin and coproporphyrin are fluores-
cent byproducts that are produced by the nonenzymatic oxidation of porphyrino-
gens. Protoporphyrin is formed by the enzymatic oxidation of protoporphyrinogen
in mitochondria. In the final step of the pathway, the intramitochondrial enzyme
heme synthase (also named ferrochelatase) catalyzes the chelation of ferrous
iron to protoporphyrin to form heme.
Humans with PP have a partial deficiency of heme synthase activity in all tissues
which have been examined, including bone marrow [7], peripheral blood cells [7-9],
liver [10], and cultured skin fibroblasts [10-12]. The level of residual activity is 10 to
30 percent of normal. Most patients have a two-to-threefold increase of ALA
synthase activity in their bone marrow and liver [7,13-16].
Cattle with PP also have a deficiency of heme synthase activity in all tissues which
have been examined: liver, kidney, heart, spleen, and lung [5,6]. The level ofresidual
activity is less than 10 percent of normal. Hepatic ALA synthase activity is increased
threefold [5].
As a result of the deficiency in heme synthase activity, protoporphyrin is accumu-
lated and excreted in excessive amounts. The biochemical hallmark of PP in humans
and cattle is an elevated level of red cell and fecal protoporphyrin [1,2,5]. Since
protoporphyrin is excreted only into bile, the urine does not contain increased
amounts ofporphyrins or porphyrin precursors in humans with the disorder. Urinary
uroporphyrin and coproporphyrin are slightly increased in cattle, however [5].
When calves with PP are placed in dim light for several weeks, their red cell
protoporphyrin levels remain unchanged, but fecal protoporphyrin falls from 1850 to
59 ,g/g [5]. The effect of sun exposure on fecal and red cell protoporphyrin levels in
humans has not been examined.
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Clinical Manifestations (Table 1)
Photosensitivity that begins early in life is the most common clinical manifestation
in both human and bovine PP [1,2,5]. After a variable exposure to sunlight (often
within minutes), humans with PP experience itching and burning ofthe sun-exposed
skin, followed by erythema and edema. Chronic skin changes may persist, with
thickening and scarring of the exposed skin. Some patients report that the photosen-
sitivity decreases with age [17].
Calves with PP which are exposed to sunlight develop cutaneous changes over
their snouts, ears, and backs that consist of edema, erythema, fissures, alopecia, and
scabbing. There is no erythrodontia. The cutaneous lesions heal when the calves are
kept out of the sun. One calf lost her photosensitivity by three years of age [5].
Hepatobiliary disease also occurs in human PP. There is a greater frequency of
cholelithiasis than in the normal population [17-21]. The gallstones contain a large
amount of protoporphyrin [18,21].
The incidence of significant hepatic disease in patients with PP probably is less
than 10 percent [21,22]. However, 15 cases have been reported inthe world literature
in which death has occurred from cirrhosis and hepatic failure [22]. At autopsy the
livers of these patients are black due to massive protoporphyrin deposition. The
deposits give a characteristic birefringence when examined by polarizing microscopy
[23] and are composed of crystals [24].
Neither hepatic disease nor cholelithiasis has been reported in bovine PP [5,6]. The
liver histology has not been examined.
Although a deficiency of heme synthase activity is the fundamental enzymatic
abnormality in PP, anemia is not an important problem in either humans or cattle.
Some patients have a slight decrease in hemoglobin and/or hematocrit levels, usually
with hypochromic, microcytic indices [21,25]. Iron kinetics and red cell survival
studies are usually normal [21,26,27]. Sideroblastic anemia has been reported in one
patient who died in hepatic failure [28]. The bone marrow of patients with PP is
normal except for fluorescence in late normoblasts and reticulocytes due to the
presence of protoporphyrin [14,27].
In bovine PP, the red cell morphology and indices are normal, and there is no
indication of abnormal hemoglobin metabolism or erythropoiesis [5,6]. The bone
marrow has not been examined.
Inheritance (Table 1)
Human PP is inherited as an autosomal dominant disease[29]. Individuals may be
asymptomatic despite biochemical abnormalities, demonstrating variable penetrance
of the clinical manifestations of the disease. A study of heme synthase activity in
cultured skin fibroblasts from members ofthree families with PP has been consistent
with autosomal dominant inheritance [11].
The inheritance pattern in bovine PP appears to be autosomal recessive. The
disease was originally found only in female calves [5,6]. Subsequently, male calves
with PP have been identified (Schwartz, personal communication). The dams of the
calves are clinically normal, but they show approximately a 50 percent reduction in
hepatic heme synthase activity [5]. These data are consistent with a recessive
inheritance pattern in which the heterozygous parents (each having a partial
deficiency of heme synthase activity) produce homozygous offspring who have
biochemical and clinical manifestations due to a severe deficiency of enzymatic
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activity. All of the reported calves with PP were sired from one clinically asympto-
matic bull, in whom heme synthase activity has not been measured.
DISCUSSION
The fundamental enzymatic defect in both human PP and bovine PP is a
deficiency of heme synthase activity. Protoporphyrin, the substrate for heme
synthase, accumulates because of this deficiency.
The liver and bone marrow, which are the major organs of heme synthesis, have
both been implicated as sources of the excess protoporphyrin in human PP. The
relative contributions of the liver and bone marrow may vary with each individual.
Two studies support a predominantly erythropoietic origin for the excess protopor-
phyrin [30,31]. The relative contributions ofthe liver and bone marrow in bovine PP
have not been determined.
The primary clinical manifestation of both human and bovine PP is photosensitiv-
ity, which begins early in life. The skin reaction is caused by exposure to light of
wavelength around 400 nm [32], which is the point at which porphyrins absorb
maximally (called the Soret band). The cutaneous changes are mainlyconfined to the
upper dermis [33,34]. Circulating protoporphyrin or protoporphyrin deposited in
skin absorbs light in the Soret region, leading to damage of the skin and/or blood
vessels in the skin [35,36]. The reason why some calves and humans with PP
apparently outgrow their photosensitivity is unknown.
Hepatobiliary disease also occurs in human PP, but is absent in bovine PP. The
explanation for this may be that the small number of calves studied to date may be
insufficient to detect a rare complication or that the calves may not develop
hepatobiliary disease until they are older. Since hepatic disease may be a critical
complication in humans with PP, its failure to occur in cattle with the disease would
limit the usefulness of this as a model.
The most striking difference between human and bovine PP is the pattern of
inheritance. Human PP is inherited as an autosomal dominant trait. Bovine PP, on
the other hand, appears to be inherited as an autosomal recessivetrait. Confirmation
requires measuring heme synthase activity in tissues of the bull which sired the
affected calves, as this should be intermediate between that observed in normal
animals and calves with protoporphyria. Ifthe measurement substantiates autosomal
recessive inheritance, it remains to be determined why cattle express the disease only
in the homozygous condition, whereas in humans it is expressed in the heterozygous
state. Direct comparison of the specific activity of heme synthase in several tissues
from cattle and humans may provide an explanation, as it is possible that the specific
activity is higher in bovinetissue(i.e., a highercatalytic rate/mg ofenzyme protein or
higher concentration of enzyme).
Despite these differences, bovine PP could provide a useful model to studyaspects
of the human disease. It will be ofparticularinterest toinvestigate factors which may
modify the production and excretion of protoporphyrin. This would include the
effect of drugs [22,37], diet [38-40], and intravenous infusion of hematin [41].
Further study of this model may also provide information which is basic to our
understanding of heme biosynthesis.
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